share_log

Piper Sandler Assumes Monopar Therapeutics at Overweight, Announces Price Target of $76

Benzinga ·  Mar 19 09:34  · Ratings

Piper Sandler analyst Biren Amin assumes Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $76.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 220

Recommended

Write a comment